Drug Trial Radar · NCT00086684
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Last checked: Nov 19, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
369
Actual
Start
Sep 2003
Primary completion
Jun 2011
Study completion Jun 2011
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 9, 2004
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.
Conditions
- Interstitial Cystitis
Interventions
Pentosan polysulfate sodium 100 mgDrug
One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
PlaceboDrug
One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
Pentosan polysulfate sodium 100 mgDrug
One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study EndpointTime frame: Baseline to Week 24
Locations
65 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Homewood, Alabama
Site not named
Anchorage, Alaska
Site not named
San Bernardino, California
Site not named
San Carlos, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Denver, Colorado
Site not named
Longmont, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Newington, Connecticut
Site not named
Norwalk, Connecticut
Site not named
Celebration, Florida
Site not named
Longwood, Florida
Site not named
Plantation, Florida
Site not named
Tampa, Florida
Site not named
Trinity, Florida
Site not named
Venice, Florida
Site not named
Weston, Florida
Site not named
Atlanta, Georgia
Site not named
Centralia, Illinois
Site not named
Evanston, Illinois
Site not named
Peoria, Illinois
Site not named
Jeffersonville, Indiana
Site not named
Dearborn, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Kalamazoo, Michigan
Site not named
St Louis, Missouri
Site not named
Henderson, Nevada
Site not named
West Orange, New Jersey
Site not named
Albany, New York
Site not named
Charlotte, North Carolina
Site not named
Concord, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Lima, Ohio
Site not named
Ponca City, Oklahoma
Site not named
Tulsa, Oklahoma
Site not named
Medford, Oregon
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.